2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Neuralstem Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NSI-189 for Major Depressive Disorder 80 Milligrams NSI-189, Placebo, 40 Milligrams NSI-189 - Major Depressive Disorder | Phase 2 | Unknown | Neuralstem Inc. | 220 | 2016-03-01 | 2017-02-24 |
| Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis Human spinal cord stem cell implantation - Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | Neuralstem Inc. | 18 | 2013-05-01 | 2015-04-20 |
Amyotrophic Lateral Sclerosis (1) · Depression (1) · Depressive Disorder, Major (1)
United States (2)
Karl Johe, Ph.D. (1)